GLP1R and atherosclerosis: This is further supported by previous findings stating that incretin antagonists, a GLP-1, and a glucose-dependent insulinotropic polypeptide, could partially attenuate the suppressive effects of DPP-4 inhibitors on atherosclerosis in diabetic mice [26].